Translational IBD research at Gut Research
The Department of Gastroenterology and Hepatology of the Academic Medical Center in Amsterdam is an expert and referral centre for IBD and has a longstanding tradition of excellent patient care combined with both clinical and fundamental research activities. Since several years now its fundamental IBD-research is bundled in the Tytgat Institute. The close collaboration between the Tytgat Institute and the Gastroenterology department is an important strength of our approach. See also IBD-AMC. We have various relevant models for colitis in our lab including acute and chronic innate driven colitis models, and acute and chronic Tcells driven colitis models. See for details on the models of choice for your compound efficacy testing this link.
In the Netherlands, but also internationally, the AMC fulfils a leading role in state-of the art treatment options for IBD. In the past the AMC IBD unit introduced the concept to treat patients with Crohn’s disease with antibodies against tumor necrosis factor (anti-TNF), a breakthrough in the therapy of this disabling disease. Over the years, other novel insights in the pathogenesis and genetics of IBD have been introduced, including the importance of IL-10 as potential treatment. The latter has led to the generation of genetically manipulated lactobacillae producing IL-10 (tested in patients with Crohn´s disease). At present the clinical IBD group is headed by Prof G. D’Haens who plays a crucial and coordinating role in phase I and II clinical trials evaluating the therapeutic potential of new biologicals. His internationally acclaimed expertise ensures timely ‘bench to bedside’ translation of results obtained in the Tytgat Institute.